BACKGROUND: Mitral valve (MV) disease is often accompanied by concomitant tricuspid valve (TV) disease. This study determined the influence of performing TV procedures in the setting of MV operations within a multiinstitutional patient population. METHODS: From 2001 to 2008, 5,495 MV operations were performed at 17 different statewide centers. Of these, 5,062 patients (age, 63.4 ± 13.0 years) underwent an MV operation and 433 (age, 64.0 ± 14.2 years) underwent combined MV and TV (MV+TV) operations. The influence of concomitant TV procedures on operative death and the composite incidence of major complications was assessed by univariate and multivariate analyses. RESULTS: Patients undergoing MV+TV were more commonly women (62.7% vs 45.5%, p < 0.001), had higher rates of heart failure (73.7% vs 50.9%, p < 0.001), and more frequently underwent reoperations (17.1% vs 7.4%, p < 0.001) compared with MV patients. Other patient characteristics, including preoperative endocarditis (8.5% vs 8.2%, p = 0.78), were similar between groups. MV replacement (63.5%) was more common than repair (36.5%, p < 0.001) in MV+TV operations, and MV+TV operations incurred longer median cardiopulmonary bypass times (181 vs 149 minutes, p < 0.001). Unadjusted operative mortality (6.0% vs 10.4%, p = 0.001) and postoperative complications were higher after MV+TV compared with MV. More important, risk adjustment showed performance of concomitant TV procedures was an independent predictor of operative death (odds ratio, 1.50; p = 0.03) and major complications (odds ratio, 1.39; p = 0.004). CONCLUSIONS: A concomitant TV operation is a proxy for more advanced valve disease. Compared with MV operations alone, simultaneous MV+TV operations are associated with elevated morbidity and death, even after risk adjustment. This elevated risk should be considered during preoperative patient risk stratification.
BACKGROUND:Mitral valve (MV) disease is often accompanied by concomitant tricuspid valve (TV) disease. This study determined the influence of performing TV procedures in the setting of MV operations within a multiinstitutional patient population. METHODS: From 2001 to 2008, 5,495 MV operations were performed at 17 different statewide centers. Of these, 5,062 patients (age, 63.4 ± 13.0 years) underwent an MV operation and 433 (age, 64.0 ± 14.2 years) underwent combined MV and TV (MV+TV) operations. The influence of concomitant TV procedures on operative death and the composite incidence of major complications was assessed by univariate and multivariate analyses. RESULTS:Patients undergoing MV+TV were more commonly women (62.7% vs 45.5%, p < 0.001), had higher rates of heart failure (73.7% vs 50.9%, p < 0.001), and more frequently underwent reoperations (17.1% vs 7.4%, p < 0.001) compared with MVpatients. Other patient characteristics, including preoperative endocarditis (8.5% vs 8.2%, p = 0.78), were similar between groups. MV replacement (63.5%) was more common than repair (36.5%, p < 0.001) in MV+TV operations, and MV+TV operations incurred longer median cardiopulmonary bypass times (181 vs 149 minutes, p < 0.001). Unadjusted operative mortality (6.0% vs 10.4%, p = 0.001) and postoperative complications were higher after MV+TV compared with MV. More important, risk adjustment showed performance of concomitant TV procedures was an independent predictor of operative death (odds ratio, 1.50; p = 0.03) and major complications (odds ratio, 1.39; p = 0.004). CONCLUSIONS: A concomitant TV operation is a proxy for more advanced valve disease. Compared with MV operations alone, simultaneous MV+TV operations are associated with elevated morbidity and death, even after risk adjustment. This elevated risk should be considered during preoperative patient risk stratification.
Authors: Steve K Singh; Gilbert H L Tang; Manjula D Maganti; Susan Armstrong; William G Williams; Tirone E David; Michael A Borger Journal: Ann Thorac Surg Date: 2006-11 Impact factor: 4.330
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce W Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Rick A Nishimura; Blase A Carabello; David P Faxon; Michael D Freed; Bruce W Lytle; Patrick T O'Gara; Robert A O'Rourke; Pravin M Shah Journal: J Am Coll Cardiol Date: 2008-09-23 Impact factor: 24.094
Authors: Vinod H Thourani; William S Weintraub; Robert A Guyton; Ellis L Jones; Willis H Williams; Sharif Elkabbani; Joseph M Craver Journal: Circulation Date: 2003-06-30 Impact factor: 29.690
Authors: Gorav Ailawadi; Brian R Swenson; Micah E Girotti; Leo M Gazoni; Benjamin B Peeler; John A Kern; Lynn M Fedoruk; Irving L Kron Journal: Ann Thorac Surg Date: 2008-07 Impact factor: 4.330
Authors: James S Gammie; Shubin Sheng; Bartley P Griffith; Eric D Peterson; J Scott Rankin; Sean M O'Brien; James M Brown Journal: Ann Thorac Surg Date: 2009-05 Impact factor: 4.330
Authors: D Dean Potter; Thoralf M Sundt; Kenton J Zehr; Joseph A Dearani; Richard C Daly; Charles J Mullany; Christopher G A McGregor; Francisco J Puga; Hartzell V Schaff; Thomas A Orszulak Journal: Ann Thorac Surg Date: 2004-07 Impact factor: 4.330
Authors: Orlando Santana; Steve Xydas; Roy F Williams; S Howard Wittels; Evin Yucel; Christos G Mihos Journal: J Thorac Dis Date: 2017-06 Impact factor: 2.895
Authors: James S Gammie; Michael W A Chu; Volkmar Falk; Jessica R Overbey; Alan J Moskowitz; Marc Gillinov; Michael J Mack; Pierre Voisine; Markus Krane; Babatunde Yerokun; Michael E Bowdish; Lenard Conradi; Steven F Bolling; Marissa A Miller; Wendy C Taddei-Peters; Neal O Jeffries; Michael K Parides; Richard Weisel; Mariell Jessup; Eric A Rose; John C Mullen; Samantha Raymond; Ellen G Moquete; Karen O'Sullivan; Mary E Marks; Alexander Iribarne; Friedhelm Beyersdorf; Michael A Borger; Arnar Geirsson; Emilia Bagiella; Judy Hung; Annetine C Gelijns; Patrick T O'Gara; Gorav Ailawadi Journal: N Engl J Med Date: 2021-11-13 Impact factor: 91.245